X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
41
PharmaCompass offers a list of Alpha Lipoic Acid API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Alpha Lipoic Acid manufacturer or Alpha Lipoic Acid supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Alpha Lipoic Acid manufacturer or Alpha Lipoic Acid supplier.
PharmaCompass also assists you with knowing the Alpha Lipoic Acid API Price utilized in the formulation of products. Alpha Lipoic Acid API Price is not always fixed or binding as the Alpha Lipoic Acid Price is obtained through a variety of data sources. The Alpha Lipoic Acid Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Heparlipon manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Heparlipon, including repackagers and relabelers. The FDA regulates Heparlipon manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Heparlipon API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Heparlipon manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Heparlipon supplier is an individual or a company that provides Heparlipon active pharmaceutical ingredient (API) or Heparlipon finished formulations upon request. The Heparlipon suppliers may include Heparlipon API manufacturers, exporters, distributors and traders.
click here to find a list of Heparlipon suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Heparlipon DMF (Drug Master File) is a document detailing the whole manufacturing process of Heparlipon active pharmaceutical ingredient (API) in detail. Different forms of Heparlipon DMFs exist exist since differing nations have different regulations, such as Heparlipon USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Heparlipon DMF submitted to regulatory agencies in the US is known as a USDMF. Heparlipon USDMF includes data on Heparlipon's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Heparlipon USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Heparlipon suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Heparlipon Drug Master File in Japan (Heparlipon JDMF) empowers Heparlipon API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Heparlipon JDMF during the approval evaluation for pharmaceutical products. At the time of Heparlipon JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Heparlipon suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Heparlipon Drug Master File in Korea (Heparlipon KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Heparlipon. The MFDS reviews the Heparlipon KDMF as part of the drug registration process and uses the information provided in the Heparlipon KDMF to evaluate the safety and efficacy of the drug.
After submitting a Heparlipon KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Heparlipon API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Heparlipon suppliers with KDMF on PharmaCompass.
A Heparlipon CEP of the European Pharmacopoeia monograph is often referred to as a Heparlipon Certificate of Suitability (COS). The purpose of a Heparlipon CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Heparlipon EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Heparlipon to their clients by showing that a Heparlipon CEP has been issued for it. The manufacturer submits a Heparlipon CEP (COS) as part of the market authorization procedure, and it takes on the role of a Heparlipon CEP holder for the record. Additionally, the data presented in the Heparlipon CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Heparlipon DMF.
A Heparlipon CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Heparlipon CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Heparlipon suppliers with CEP (COS) on PharmaCompass.
A Heparlipon written confirmation (Heparlipon WC) is an official document issued by a regulatory agency to a Heparlipon manufacturer, verifying that the manufacturing facility of a Heparlipon active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Heparlipon APIs or Heparlipon finished pharmaceutical products to another nation, regulatory agencies frequently require a Heparlipon WC (written confirmation) as part of the regulatory process.
click here to find a list of Heparlipon suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Heparlipon as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Heparlipon API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Heparlipon as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Heparlipon and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Heparlipon NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Heparlipon suppliers with NDC on PharmaCompass.
Heparlipon Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Heparlipon GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Heparlipon GMP manufacturer or Heparlipon GMP API supplier for your needs.
A Heparlipon CoA (Certificate of Analysis) is a formal document that attests to Heparlipon's compliance with Heparlipon specifications and serves as a tool for batch-level quality control.
Heparlipon CoA mostly includes findings from lab analyses of a specific batch. For each Heparlipon CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Heparlipon may be tested according to a variety of international standards, such as European Pharmacopoeia (Heparlipon EP), Heparlipon JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Heparlipon USP).
Market Place
